Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
NCT04581629Phase 2Completed
- Sponsor
- Calcilytix Therapeutics
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1), sponsored by Calcilytix Therapeutics. Started Sep 2020; status: completed.
02
Drugs
encaleret
03
Conditions
autosomal dominant hypocalcemia type 1 (ADH1)
Beyond the preview
Go deeper on NCT04581629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581629.